Anteris Technologies Global Corp.
Get $10 bonus on your first $100 deposit for AVR
Get $10 bonus on your first $100 deposit for AVR
Anteris Technologies Global Corp. (AVR) Stock Competitors & Peer Comparison
See (AVR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AVR | $5.50 | +3.38% | 202.3M | -2.16 | -$2.55 | N/A |
| ABT | $102.87 | +0.48% | 178.8B | 27.65 | $3.72 | +2.33% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $331.54 | +0.65% | 126.9B | 39.47 | $8.40 | +1.04% |
| MDT | $86.63 | +0.66% | 111.2B | 24.20 | $3.58 | +3.28% |
| BSX | $62.82 | +1.32% | 93.2B | 32.38 | $1.94 | N/A |
| EW | $81.05 | -0.26% | 47.1B | 44.78 | $1.81 | N/A |
| BRKRP | $290.04 | +0.88% | 44B | N/A | N/A | +0.54% |
| PHG | $27.11 | -0.66% | 26B | 25.10 | $1.08 | +3.27% |
| DXCM | $62.22 | -0.24% | 24.3B | 29.77 | $2.09 | N/A |
Stock Comparison
AVR vs ABT Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, ABT has a market cap of 178.8B. Regarding current trading prices, AVR is priced at $5.50, while ABT trades at $102.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas ABT's P/E ratio is 27.65. In terms of profitability, AVR's ROE is -5.28%, compared to ABT's ROE of +0.13%. Regarding short-term risk, AVR is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check ABT's competition here
AVR vs BSX-PA Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, AVR is priced at $5.50, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, AVR's ROE is -5.28%, compared to BSX-PA's ROE of +0.13%. Regarding short-term risk, AVR is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check BSX-PA's competition here
AVR vs SYK Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, SYK has a market cap of 126.9B. Regarding current trading prices, AVR is priced at $5.50, while SYK trades at $331.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas SYK's P/E ratio is 39.47. In terms of profitability, AVR's ROE is -5.28%, compared to SYK's ROE of +0.15%. Regarding short-term risk, AVR is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check SYK's competition here
AVR vs MDT Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, MDT has a market cap of 111.2B. Regarding current trading prices, AVR is priced at $5.50, while MDT trades at $86.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas MDT's P/E ratio is 24.20. In terms of profitability, AVR's ROE is -5.28%, compared to MDT's ROE of +0.10%. Regarding short-term risk, AVR is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check MDT's competition here
AVR vs BSX Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, BSX has a market cap of 93.2B. Regarding current trading prices, AVR is priced at $5.50, while BSX trades at $62.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas BSX's P/E ratio is 32.38. In terms of profitability, AVR's ROE is -5.28%, compared to BSX's ROE of +0.13%. Regarding short-term risk, AVR is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check BSX's competition here
AVR vs EW Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, EW has a market cap of 47.1B. Regarding current trading prices, AVR is priced at $5.50, while EW trades at $81.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas EW's P/E ratio is 44.78. In terms of profitability, AVR's ROE is -5.28%, compared to EW's ROE of +0.10%. Regarding short-term risk, AVR is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check EW's competition here
AVR vs BRKRP Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, BRKRP has a market cap of 44B. Regarding current trading prices, AVR is priced at $5.50, while BRKRP trades at $290.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas BRKRP's P/E ratio is N/A. In terms of profitability, AVR's ROE is -5.28%, compared to BRKRP's ROE of -0.00%. Regarding short-term risk, AVR is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check BRKRP's competition here
AVR vs PHG Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, PHG has a market cap of 26B. Regarding current trading prices, AVR is priced at $5.50, while PHG trades at $27.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas PHG's P/E ratio is 25.10. In terms of profitability, AVR's ROE is -5.28%, compared to PHG's ROE of +0.08%. Regarding short-term risk, AVR is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check PHG's competition here
AVR vs DXCM Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, DXCM has a market cap of 24.3B. Regarding current trading prices, AVR is priced at $5.50, while DXCM trades at $62.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas DXCM's P/E ratio is 29.77. In terms of profitability, AVR's ROE is -5.28%, compared to DXCM's ROE of +0.32%. Regarding short-term risk, AVR is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check DXCM's competition here
AVR vs STE Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, STE has a market cap of 21.5B. Regarding current trading prices, AVR is priced at $5.50, while STE trades at $218.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas STE's P/E ratio is 30.50. In terms of profitability, AVR's ROE is -5.28%, compared to STE's ROE of +0.10%. Regarding short-term risk, AVR is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check STE's competition here
AVR vs ZBH Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, ZBH has a market cap of 18B. Regarding current trading prices, AVR is priced at $5.50, while ZBH trades at $90.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas ZBH's P/E ratio is 25.60. In terms of profitability, AVR's ROE is -5.28%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, AVR is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check ZBH's competition here
AVR vs ABMD Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, AVR is priced at $5.50, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas ABMD's P/E ratio is 65.36. In terms of profitability, AVR's ROE is -5.28%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, AVR is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check ABMD's competition here
AVR vs PODD Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, PODD has a market cap of 14.4B. Regarding current trading prices, AVR is priced at $5.50, while PODD trades at $204.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas PODD's P/E ratio is 58.71. In terms of profitability, AVR's ROE is -5.28%, compared to PODD's ROE of +0.17%. Regarding short-term risk, AVR is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check PODD's competition here
AVR vs SNN Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, SNN has a market cap of 13.7B. Regarding current trading prices, AVR is priced at $5.50, while SNN trades at $32.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas SNN's P/E ratio is 22.47. In terms of profitability, AVR's ROE is -5.28%, compared to SNN's ROE of +0.12%. Regarding short-term risk, AVR is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check SNN's competition here
AVR vs PEN Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, PEN has a market cap of 13B. Regarding current trading prices, AVR is priced at $5.50, while PEN trades at $330.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas PEN's P/E ratio is 73.25. In terms of profitability, AVR's ROE is -5.28%, compared to PEN's ROE of +0.13%. Regarding short-term risk, AVR is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check PEN's competition here
AVR vs SWAV Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, AVR is priced at $5.50, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas SWAV's P/E ratio is 78.76. In terms of profitability, AVR's ROE is -5.28%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, AVR is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check SWAV's competition here
AVR vs ALGN Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, ALGN has a market cap of 12.2B. Regarding current trading prices, AVR is priced at $5.50, while ALGN trades at $170.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas ALGN's P/E ratio is 30.14. In terms of profitability, AVR's ROE is -5.28%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, AVR is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check ALGN's competition here
AVR vs GMED Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, GMED has a market cap of 11.9B. Regarding current trading prices, AVR is priced at $5.50, while GMED trades at $87.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas GMED's P/E ratio is 22.43. In terms of profitability, AVR's ROE is -5.28%, compared to GMED's ROE of +0.12%. Regarding short-term risk, AVR is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check GMED's competition here
AVR vs BIO-B Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, BIO-B has a market cap of 7.6B. Regarding current trading prices, AVR is priced at $5.50, while BIO-B trades at $280.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas BIO-B's P/E ratio is 10.06. In terms of profitability, AVR's ROE is -5.28%, compared to BIO-B's ROE of +0.11%. Regarding short-term risk, AVR is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check BIO-B's competition here
AVR vs BIO Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, BIO has a market cap of 7.6B. Regarding current trading prices, AVR is priced at $5.50, while BIO trades at $279.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas BIO's P/E ratio is 10.05. In terms of profitability, AVR's ROE is -5.28%, compared to BIO's ROE of +0.11%. Regarding short-term risk, AVR is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check BIO's competition here
AVR vs GKOS Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, GKOS has a market cap of 6.5B. Regarding current trading prices, AVR is priced at $5.50, while GKOS trades at $112.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas GKOS's P/E ratio is -34.38. In terms of profitability, AVR's ROE is -5.28%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, AVR is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check GKOS's competition here
AVR vs BRKR Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, BRKR has a market cap of 5.6B. Regarding current trading prices, AVR is priced at $5.50, while BRKR trades at $36.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas BRKR's P/E ratio is -245.07. In terms of profitability, AVR's ROE is -5.28%, compared to BRKR's ROE of -0.00%. Regarding short-term risk, AVR is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.Check BRKR's competition here
AVR vs NARI Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, AVR is priced at $5.50, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas NARI's P/E ratio is -59.24. In terms of profitability, AVR's ROE is -5.28%, compared to NARI's ROE of -0.00%. Regarding short-term risk, AVR is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check NARI's competition here
AVR vs IRTC Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, AVR is priced at $5.50, while IRTC trades at $116.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas IRTC's P/E ratio is -84.03. In terms of profitability, AVR's ROE is -5.28%, compared to IRTC's ROE of -0.38%. Regarding short-term risk, AVR is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check IRTC's competition here
AVR vs AXNX Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, AVR is priced at $5.50, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas AXNX's P/E ratio is -709.80. In terms of profitability, AVR's ROE is -5.28%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, AVR is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check AXNX's competition here
AVR vs LIVN Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, LIVN has a market cap of 3.5B. Regarding current trading prices, AVR is priced at $5.50, while LIVN trades at $63.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas LIVN's P/E ratio is -14.33. In terms of profitability, AVR's ROE is -5.28%, compared to LIVN's ROE of -0.21%. Regarding short-term risk, AVR is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check LIVN's competition here
AVR vs TMDX Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, TMDX has a market cap of 3.5B. Regarding current trading prices, AVR is priced at $5.50, while TMDX trades at $100.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas TMDX's P/E ratio is 20.68. In terms of profitability, AVR's ROE is -5.28%, compared to TMDX's ROE of +0.54%. Regarding short-term risk, AVR is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check TMDX's competition here
AVR vs ITGR Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, AVR is priced at $5.50, while ITGR trades at $86.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas ITGR's P/E ratio is 30.05. In terms of profitability, AVR's ROE is -5.28%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, AVR is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check ITGR's competition here
AVR vs NUVA Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, AVR is priced at $5.50, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas NUVA's P/E ratio is 75.00. In terms of profitability, AVR's ROE is -5.28%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, AVR is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check NUVA's competition here
AVR vs AXGN Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, AXGN has a market cap of 1.8B. Regarding current trading prices, AVR is priced at $5.50, while AXGN trades at $34.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas AXGN's P/E ratio is -101.29. In terms of profitability, AVR's ROE is -5.28%, compared to AXGN's ROE of -0.13%. Regarding short-term risk, AVR is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check AXGN's competition here
AVR vs ESTA Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, ESTA has a market cap of 1.7B. Regarding current trading prices, AVR is priced at $5.50, while ESTA trades at $58.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas ESTA's P/E ratio is -33.90. In terms of profitability, AVR's ROE is -5.28%, compared to ESTA's ROE of -2.02%. Regarding short-term risk, AVR is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check ESTA's competition here
AVR vs ATEC Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, AVR is priced at $5.50, while ATEC trades at $10.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas ATEC's P/E ratio is -11.28. In terms of profitability, AVR's ROE is -5.28%, compared to ATEC's ROE of -17.60%. Regarding short-term risk, AVR is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check ATEC's competition here
AVR vs AORT Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, AORT has a market cap of 1.6B. Regarding current trading prices, AVR is priced at $5.50, while AORT trades at $34.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas AORT's P/E ratio is 162.90. In terms of profitability, AVR's ROE is -5.28%, compared to AORT's ROE of +0.02%. Regarding short-term risk, AVR is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check AORT's competition here
AVR vs AHCO Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, AHCO has a market cap of 1.6B. Regarding current trading prices, AVR is priced at $5.50, while AHCO trades at $12.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas AHCO's P/E ratio is -23.13. In terms of profitability, AVR's ROE is -5.28%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, AVR is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check AHCO's competition here
AVR vs INSP Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, INSP has a market cap of 1.6B. Regarding current trading prices, AVR is priced at $5.50, while INSP trades at $54.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas INSP's P/E ratio is 11.25. In terms of profitability, AVR's ROE is -5.28%, compared to INSP's ROE of +0.21%. Regarding short-term risk, AVR is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.Check INSP's competition here
AVR vs PMI Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, PMI has a market cap of 1.5B. Regarding current trading prices, AVR is priced at $5.50, while PMI trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas PMI's P/E ratio is -1.27. In terms of profitability, AVR's ROE is -5.28%, compared to PMI's ROE of +2.17%. Regarding short-term risk, AVR is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.Check PMI's competition here
AVR vs UFPT Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, UFPT has a market cap of 1.5B. Regarding current trading prices, AVR is priced at $5.50, while UFPT trades at $192.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas UFPT's P/E ratio is 21.95. In terms of profitability, AVR's ROE is -5.28%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, AVR is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check UFPT's competition here
AVR vs PRCT Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, PRCT has a market cap of 1.4B. Regarding current trading prices, AVR is priced at $5.50, while PRCT trades at $25.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas PRCT's P/E ratio is -14.60. In terms of profitability, AVR's ROE is -5.28%, compared to PRCT's ROE of -0.25%. Regarding short-term risk, AVR is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check PRCT's competition here
AVR vs HSKA Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, AVR is priced at $5.50, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas HSKA's P/E ratio is -62.49. In terms of profitability, AVR's ROE is -5.28%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, AVR is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check HSKA's competition here
AVR vs TNDM Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, AVR is priced at $5.50, while TNDM trades at $18.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas TNDM's P/E ratio is -6.12. In terms of profitability, AVR's ROE is -5.28%, compared to TNDM's ROE of -1.42%. Regarding short-term risk, AVR is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check TNDM's competition here
AVR vs IRMD Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, AVR is priced at $5.50, while IRMD trades at $96.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas IRMD's P/E ratio is 54.99. In terms of profitability, AVR's ROE is -5.28%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, AVR is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check IRMD's competition here
AVR vs SILK Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, AVR is priced at $5.50, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas SILK's P/E ratio is -18.96. In terms of profitability, AVR's ROE is -5.28%, compared to SILK's ROE of -0.35%. Regarding short-term risk, AVR is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check SILK's competition here
AVR vs FNA Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, AVR is priced at $5.50, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas FNA's P/E ratio is -19.83. In terms of profitability, AVR's ROE is -5.28%, compared to FNA's ROE of -0.17%. Regarding short-term risk, AVR is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check FNA's competition here
AVR vs CNMD Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, AVR is priced at $5.50, while CNMD trades at $34.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas CNMD's P/E ratio is 23.04. In terms of profitability, AVR's ROE is -5.28%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, AVR is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check CNMD's competition here
AVR vs BFLY Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, BFLY has a market cap of 1B. Regarding current trading prices, AVR is priced at $5.50, while BFLY trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas BFLY's P/E ratio is -13.26. In terms of profitability, AVR's ROE is -5.28%, compared to BFLY's ROE of -0.35%. Regarding short-term risk, AVR is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.Check BFLY's competition here
AVR vs SSII Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, SSII has a market cap of 971.8M. Regarding current trading prices, AVR is priced at $5.50, while SSII trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas SSII's P/E ratio is -83.33. In terms of profitability, AVR's ROE is -5.28%, compared to SSII's ROE of -0.30%. Regarding short-term risk, AVR is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.Check SSII's competition here
AVR vs LMRI Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, LMRI has a market cap of 884.2M. Regarding current trading prices, AVR is priced at $5.50, while LMRI trades at $9.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas LMRI's P/E ratio is -14.17. In terms of profitability, AVR's ROE is -5.28%, compared to LMRI's ROE of -0.18%. Regarding short-term risk, AVR is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.Check LMRI's competition here
AVR vs INMD Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, INMD has a market cap of 873.7M. Regarding current trading prices, AVR is priced at $5.50, while INMD trades at $13.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas INMD's P/E ratio is 9.64. In terms of profitability, AVR's ROE is -5.28%, compared to INMD's ROE of +0.15%. Regarding short-term risk, AVR is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check INMD's competition here
AVR vs CSII Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, AVR is priced at $5.50, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas CSII's P/E ratio is -20.83. In terms of profitability, AVR's ROE is -5.28%, compared to CSII's ROE of -0.14%. Regarding short-term risk, AVR is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check CSII's competition here
AVR vs IART Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, IART has a market cap of 742.7M. Regarding current trading prices, AVR is priced at $5.50, while IART trades at $9.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas IART's P/E ratio is -1.41. In terms of profitability, AVR's ROE is -5.28%, compared to IART's ROE of -0.44%. Regarding short-term risk, AVR is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check IART's competition here
AVR vs CRY Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, AVR is priced at $5.50, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas CRY's P/E ratio is 425.71. In terms of profitability, AVR's ROE is -5.28%, compared to CRY's ROE of +0.02%. Regarding short-term risk, AVR is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check CRY's competition here
AVR vs CBLL Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, CBLL has a market cap of 699M. Regarding current trading prices, AVR is priced at $5.50, while CBLL trades at $18.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas CBLL's P/E ratio is -12.63. In terms of profitability, AVR's ROE is -5.28%, compared to CBLL's ROE of -0.32%. Regarding short-term risk, AVR is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check CBLL's competition here
AVR vs AVNS Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, AVNS has a market cap of 648.7M. Regarding current trading prices, AVR is priced at $5.50, while AVNS trades at $13.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas AVNS's P/E ratio is -8.89. In terms of profitability, AVR's ROE is -5.28%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, AVR is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check AVNS's competition here
AVR vs SRDX Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, AVR is priced at $5.50, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas SRDX's P/E ratio is -34.66. In terms of profitability, AVR's ROE is -5.28%, compared to SRDX's ROE of -0.16%. Regarding short-term risk, AVR is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check SRDX's competition here
AVR vs BVS Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, BVS has a market cap of 604.3M. Regarding current trading prices, AVR is priced at $5.50, while BVS trades at $8.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas BVS's P/E ratio is 27.18. In terms of profitability, AVR's ROE is -5.28%, compared to BVS's ROE of +0.14%. Regarding short-term risk, AVR is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check BVS's competition here
AVR vs CTKB Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, CTKB has a market cap of 582.3M. Regarding current trading prices, AVR is priced at $5.50, while CTKB trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas CTKB's P/E ratio is -8.71. In terms of profitability, AVR's ROE is -5.28%, compared to CTKB's ROE of -0.18%. Regarding short-term risk, AVR is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check CTKB's competition here
AVR vs APEN Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, AVR is priced at $5.50, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas APEN's P/E ratio is -9.43. In terms of profitability, AVR's ROE is -5.28%, compared to APEN's ROE of -0.85%. Regarding short-term risk, AVR is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check APEN's competition here
AVR vs SIBN Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, SIBN has a market cap of 579.4M. Regarding current trading prices, AVR is priced at $5.50, while SIBN trades at $13.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas SIBN's P/E ratio is -29.82. In terms of profitability, AVR's ROE is -5.28%, compared to SIBN's ROE of -0.11%. Regarding short-term risk, AVR is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check SIBN's competition here
AVR vs TCMD Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, TCMD has a market cap of 559.7M. Regarding current trading prices, AVR is priced at $5.50, while TCMD trades at $24.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas TCMD's P/E ratio is 30.00. In terms of profitability, AVR's ROE is -5.28%, compared to TCMD's ROE of +0.09%. Regarding short-term risk, AVR is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.Check TCMD's competition here
AVR vs ZIMV Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, AVR is priced at $5.50, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, AVR's ROE is -5.28%, compared to ZIMV's ROE of -0.05%. Regarding short-term risk, AVR is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check ZIMV's competition here
AVR vs BWAY Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, BWAY has a market cap of 532.3M. Regarding current trading prices, AVR is priced at $5.50, while BWAY trades at $13.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas BWAY's P/E ratio is 75.39. In terms of profitability, AVR's ROE is -5.28%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, AVR is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check BWAY's competition here
AVR vs NPCE Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, NPCE has a market cap of 493.2M. Regarding current trading prices, AVR is priced at $5.50, while NPCE trades at $14.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas NPCE's P/E ratio is -22.20. In terms of profitability, AVR's ROE is -5.28%, compared to NPCE's ROE of -1.06%. Regarding short-term risk, AVR is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check NPCE's competition here
AVR vs OFIX Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, OFIX has a market cap of 462.9M. Regarding current trading prices, AVR is priced at $5.50, while OFIX trades at $11.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas OFIX's P/E ratio is -4.95. In terms of profitability, AVR's ROE is -5.28%, compared to OFIX's ROE of -0.20%. Regarding short-term risk, AVR is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check OFIX's competition here
AVR vs VREX Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, VREX has a market cap of 440.2M. Regarding current trading prices, AVR is priced at $5.50, while VREX trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas VREX's P/E ratio is -6.40. In terms of profitability, AVR's ROE is -5.28%, compared to VREX's ROE of -0.14%. Regarding short-term risk, AVR is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check VREX's competition here
AVR vs KIDS Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, KIDS has a market cap of 406M. Regarding current trading prices, AVR is priced at $5.50, while KIDS trades at $16.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas KIDS's P/E ratio is -9.50. In terms of profitability, AVR's ROE is -5.28%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, AVR is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check KIDS's competition here
AVR vs PACB Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, PACB has a market cap of 404.7M. Regarding current trading prices, AVR is priced at $5.50, while PACB trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas PACB's P/E ratio is -0.74. In terms of profitability, AVR's ROE is -5.28%, compared to PACB's ROE of -11.23%. Regarding short-term risk, AVR is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check PACB's competition here
AVR vs VMD Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, VMD has a market cap of 371.7M. Regarding current trading prices, AVR is priced at $5.50, while VMD trades at $9.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas VMD's P/E ratio is 26.03. In terms of profitability, AVR's ROE is -5.28%, compared to VMD's ROE of +0.11%. Regarding short-term risk, AVR is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check VMD's competition here
AVR vs CERS Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, CERS has a market cap of 357.4M. Regarding current trading prices, AVR is priced at $5.50, while CERS trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas CERS's P/E ratio is -23.25. In terms of profitability, AVR's ROE is -5.28%, compared to CERS's ROE of -0.26%. Regarding short-term risk, AVR is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check CERS's competition here
AVR vs LAB Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, LAB has a market cap of 354.1M. Regarding current trading prices, AVR is priced at $5.50, while LAB trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas LAB's P/E ratio is -6.05. In terms of profitability, AVR's ROE is -5.28%, compared to LAB's ROE of -0.18%. Regarding short-term risk, AVR is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check LAB's competition here
AVR vs DCTH Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, DCTH has a market cap of 334.6M. Regarding current trading prices, AVR is priced at $5.50, while DCTH trades at $9.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas DCTH's P/E ratio is 137.57. In terms of profitability, AVR's ROE is -5.28%, compared to DCTH's ROE of +0.03%. Regarding short-term risk, AVR is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check DCTH's competition here
AVR vs CATX Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, CATX has a market cap of 324.9M. Regarding current trading prices, AVR is priced at $5.50, while CATX trades at $4.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas CATX's P/E ratio is -3.13. In terms of profitability, AVR's ROE is -5.28%, compared to CATX's ROE of -0.41%. Regarding short-term risk, AVR is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.Check CATX's competition here
AVR vs SMLR Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, AVR is priced at $5.50, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas SMLR's P/E ratio is 3.92. In terms of profitability, AVR's ROE is -5.28%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, AVR is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check SMLR's competition here
AVR vs SENS Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, SENS has a market cap of 288.2M. Regarding current trading prices, AVR is priced at $5.50, while SENS trades at $6.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas SENS's P/E ratio is -4.16. In terms of profitability, AVR's ROE is -5.28%, compared to SENS's ROE of -1.04%. Regarding short-term risk, AVR is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.Check SENS's competition here
AVR vs CLPT Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, CLPT has a market cap of 278.7M. Regarding current trading prices, AVR is priced at $5.50, while CLPT trades at $9.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas CLPT's P/E ratio is -10.41. In terms of profitability, AVR's ROE is -5.28%, compared to CLPT's ROE of -1.22%. Regarding short-term risk, AVR is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.Check CLPT's competition here
AVR vs RXST Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, RXST has a market cap of 274M. Regarding current trading prices, AVR is priced at $5.50, while RXST trades at $6.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas RXST's P/E ratio is -6.99. In terms of profitability, AVR's ROE is -5.28%, compared to RXST's ROE of -0.14%. Regarding short-term risk, AVR is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.Check RXST's competition here
AVR vs MASS Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, MASS has a market cap of 247.1M. Regarding current trading prices, AVR is priced at $5.50, while MASS trades at $6.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas MASS's P/E ratio is -7.11. In terms of profitability, AVR's ROE is -5.28%, compared to MASS's ROE of +0.13%. Regarding short-term risk, AVR is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.Check MASS's competition here
AVR vs MGRM Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, AVR is priced at $5.50, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas MGRM's P/E ratio is -11.11. In terms of profitability, AVR's ROE is -5.28%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, AVR is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check MGRM's competition here
AVR vs CVRX Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, CVRX has a market cap of 237.1M. Regarding current trading prices, AVR is priced at $5.50, while CVRX trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas CVRX's P/E ratio is -4.42. In terms of profitability, AVR's ROE is -5.28%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, AVR is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check CVRX's competition here
AVR vs NVRO Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, AVR is priced at $5.50, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas NVRO's P/E ratio is -1.91. In terms of profitability, AVR's ROE is -5.28%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, AVR is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check NVRO's competition here
AVR vs ANIK Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, ANIK has a market cap of 213.4M. Regarding current trading prices, AVR is priced at $5.50, while ANIK trades at $14.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas ANIK's P/E ratio is -21.14. In terms of profitability, AVR's ROE is -5.28%, compared to ANIK's ROE of -0.07%. Regarding short-term risk, AVR is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check ANIK's competition here
AVR vs EYES Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, AVR is priced at $5.50, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas EYES's P/E ratio is N/A. In terms of profitability, AVR's ROE is -5.28%, compared to EYES's ROE of -3.17%. Regarding short-term risk, AVR is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check EYES's competition here
AVR vs PROF Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, PROF has a market cap of 194.6M. Regarding current trading prices, AVR is priced at $5.50, while PROF trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas PROF's P/E ratio is -4.56. In terms of profitability, AVR's ROE is -5.28%, compared to PROF's ROE of -0.80%. Regarding short-term risk, AVR is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check PROF's competition here
AVR vs ELMD Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, ELMD has a market cap of 194.3M. Regarding current trading prices, AVR is priced at $5.50, while ELMD trades at $23.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas ELMD's P/E ratio is 22.61. In terms of profitability, AVR's ROE is -5.28%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, AVR is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check ELMD's competition here
AVR vs BSGM Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, AVR is priced at $5.50, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas BSGM's P/E ratio is -5.81. In terms of profitability, AVR's ROE is -5.28%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, AVR is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.Check BSGM's competition here
AVR vs SGHT Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, SGHT has a market cap of 190.1M. Regarding current trading prices, AVR is priced at $5.50, while SGHT trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas SGHT's P/E ratio is -4.76. In terms of profitability, AVR's ROE is -5.28%, compared to SGHT's ROE of -0.56%. Regarding short-term risk, AVR is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check SGHT's competition here
AVR vs MDGS Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, AVR is priced at $5.50, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas MDGS's P/E ratio is -0.27. In terms of profitability, AVR's ROE is -5.28%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, AVR is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.Check MDGS's competition here
AVR vs QTRX Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, QTRX has a market cap of 177.9M. Regarding current trading prices, AVR is priced at $5.50, while QTRX trades at $3.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas QTRX's P/E ratio is -1.51. In terms of profitability, AVR's ROE is -5.28%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, AVR is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.Check QTRX's competition here
AVR vs QTI Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, QTI has a market cap of 177.7M. Regarding current trading prices, AVR is priced at $5.50, while QTI trades at $6.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas QTI's P/E ratio is -3.26. In terms of profitability, AVR's ROE is -5.28%, compared to QTI's ROE of +3.64%. Regarding short-term risk, AVR is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.Check QTI's competition here
AVR vs INGN Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, INGN has a market cap of 169.1M. Regarding current trading prices, AVR is priced at $5.50, while INGN trades at $6.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas INGN's P/E ratio is -7.22. In terms of profitability, AVR's ROE is -5.28%, compared to INGN's ROE of -0.12%. Regarding short-term risk, AVR is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check INGN's competition here
AVR vs QIPT Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, AVR is priced at $5.50, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas QIPT's P/E ratio is -15.87. In terms of profitability, AVR's ROE is -5.28%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, AVR is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check QIPT's competition here
AVR vs TLSI Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, TLSI has a market cap of 160.7M. Regarding current trading prices, AVR is priced at $5.50, while TLSI trades at $4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas TLSI's P/E ratio is -2.30. In terms of profitability, AVR's ROE is -5.28%, compared to TLSI's ROE of +1.37%. Regarding short-term risk, AVR is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check TLSI's competition here
AVR vs APYX Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, APYX has a market cap of 153.9M. Regarding current trading prices, AVR is priced at $5.50, while APYX trades at $3.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas APYX's P/E ratio is -13.63. In terms of profitability, AVR's ROE is -5.28%, compared to APYX's ROE of -1.18%. Regarding short-term risk, AVR is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check APYX's competition here
AVR vs NNOX Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, NNOX has a market cap of 153.7M. Regarding current trading prices, AVR is priced at $5.50, while NNOX trades at $2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas NNOX's P/E ratio is -2.74. In terms of profitability, AVR's ROE is -5.28%, compared to NNOX's ROE of -0.32%. Regarding short-term risk, AVR is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check NNOX's competition here
AVR vs SNWV Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, SNWV has a market cap of 145.2M. Regarding current trading prices, AVR is priced at $5.50, while SNWV trades at $16.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas SNWV's P/E ratio is 41.22. In terms of profitability, AVR's ROE is -5.28%, compared to SNWV's ROE of -1.42%. Regarding short-term risk, AVR is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check SNWV's competition here
AVR vs EDAP Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, EDAP has a market cap of 127.1M. Regarding current trading prices, AVR is priced at $5.50, while EDAP trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas EDAP's P/E ratio is -4.35. In terms of profitability, AVR's ROE is -5.28%, compared to EDAP's ROE of -1.15%. Regarding short-term risk, AVR is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.Check EDAP's competition here
AVR vs LUCD Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, LUCD has a market cap of 116.6M. Regarding current trading prices, AVR is priced at $5.50, while LUCD trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas LUCD's P/E ratio is -1.65. In terms of profitability, AVR's ROE is -5.28%, compared to LUCD's ROE of -5.91%. Regarding short-term risk, AVR is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check LUCD's competition here
AVR vs FONR Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, FONR has a market cap of 114.8M. Regarding current trading prices, AVR is priced at $5.50, while FONR trades at $18.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas FONR's P/E ratio is 16.17. In terms of profitability, AVR's ROE is -5.28%, compared to FONR's ROE of +0.04%. Regarding short-term risk, AVR is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check FONR's competition here
AVR vs ICAD Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, AVR is priced at $5.50, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas ICAD's P/E ratio is -20.37. In terms of profitability, AVR's ROE is -5.28%, compared to ICAD's ROE of -0.06%. Regarding short-term risk, AVR is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check ICAD's competition here
AVR vs RPID Comparison April 2026
AVR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR stands at 202.3M. In comparison, RPID has a market cap of 103.2M. Regarding current trading prices, AVR is priced at $5.50, while RPID trades at $2.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR currently has a P/E ratio of -2.16, whereas RPID's P/E ratio is -2.27. In terms of profitability, AVR's ROE is -5.28%, compared to RPID's ROE of -0.95%. Regarding short-term risk, AVR is more volatile compared to RPID. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.Check RPID's competition here